Psychiatry & Co-Morbid Medical Conditions- Renal (Q.1)

 

Psychiatry & Co-Morbid Medical Conditions: Renal

 

 

This question series will focus on clinically relevant questions related to the role of psychotropic medications in patients with underlying renal disease. 

 

(Q.1): Which of the following medication will need dosage adjustment in patient with schizophrenia and moderate renal impairment (eCrCl = 31-50 mL/min)?

  1. Paliperidone
  2. Olanzapine
  3. Clozapine
  4. Quetiapine

Answer: (1) Paliperidone.

 

Paliperidone:

Dosing must be individualized according to renal function status:

  • For mild renal impairment (creatinine clearance ≥50 mL/min to < 80 mL/min): recommended initial dose is 3 mg/day, which may be increased to a maximum of 6 mg/day based on clinical response and tolerability.

 

  • For moderate to severe renal impairment (creatinine clearance ≥10 mL/min to <50 mL/min):  recommended initial dose is 1.5 mg mg/day, which may be increased to a maximum of 3 mg/day after clinical reassessment.

 

  • For patients with creatinine clearance < 10 mL/min: paliperidone is not been studies so use is not recommended in such patients.

 

Source: INVEGA® (paliperidone) package insert.

Olanzapine:

Renal dysfunction alone is unlikely to have a major impact on the pharmacokinetics of olanzapine:-
  • Because olanzapine is highly metabolized before excretion and only 7% of the drug is excreted unchanged.

 

  • Olanzapine is not removed by dialysis.

 

Source: ZYPREXA (olanzapine) package insert.

Clozapine:

  • No specific pharmacokinetic studies were conducted to investigate the effects of renal or hepatic impairment on the pharmacokinetics of clozapine .

 

  • Higher clozapine plasma concentrations are likely in patients with significant renal or hepatic impairment when given usual doses. 

 

Source: CLOZARIL® (clozapine) package insert.

Quetiapine:

According to medications package insert:-

  • Patients with severe renal impairment (Clcr=10-30 mL/min/1.73 m2) had a 25% lower mean oral clearance than normal subjects (Clcr > 80 mL/min/1.73 m2), but plasma quetiapine concentrations in the subjects with renal insufficiency were within the range of concentrations seen in normal subjects receiving the same dose.

 

  • Dosage adjustment is therefore not needed in these patients.

 

Source: SEROQUEL (quetiapine fumarate) package insert.

Please do post your questions or comments below. 


Dr. Harvinder Singh, M.D. (Admin)


Enroll in our online course to have access to all important clinically relevant psychiatry topics in one place.


Related Articles